CRYOPORT, INC. Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31)
CRYOPORT, INC. (CYRX) reported Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) of $1.60 thousand for the 12-month period ending 2013-03-31, per its 10-K filed 2013-06-25.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefitContinuingOperations · last filed 2013-06-25
- CRYOPORT, INC. income tax expense (benefit), continuing operations (deprecated 2013-01-31) for fiscal 2013 was $1.60K, a 0.00% change from fiscal 2012.
- CRYOPORT, INC. income tax expense (benefit), continuing operations (deprecated 2013-01-31) for fiscal 2012 was $1.60K.
| Period end | Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) 12 month |
|---|---|
| 2013-03-31 | $1.60K 10-K · filed 2013-06-25 |
| 2012-03-31 | $1.60K 10-K · filed 2013-06-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |